Hemodynamic effects of the antithrombotic drug cilostazol in chronic arterial occlusion in the extremities

Abstract

An open clinical trial was performed to determine whether or not the antithrombotic drug cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-qui nolinone, OPC-13013) at 150 mg/day would increase ankle blood flow in 13 lower extremities in 9 patients with chronic arterial occlusion. After 2 weeks of treatment, ankle blood flow in the lower extremities increased by a mean of 16.16 +/- 7.08% (p less than 0.05, t-test) over the initial level. From these results, it was concluded that cilostazol has a significant beneficial hemodynamic effect on chronic arterial occlusion in the extremities.